Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
Amita PatnaikGlen J WeissDrew W RascoLisa BlaydornAmy MirabellaMurali BeeramWei GuoSharon LuHadi DanaeeKristen McEachernEllie ImJasgit C SachdevPublished in: Cancer chemotherapy and pharmacology (2021)
ClinicalTrials.gov, NCT02715284. Registration date: March 9, 2016.
Keyphrases